A Multi-centre, Randomised, Placebo Controlled, Double Blinded, Multiple Dose Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A Subjects (Explorer3)
Phase of Trial: Phase I
Latest Information Update: 19 Apr 2017
At a glance
- Drugs Concizumab (Primary)
- Indications Haemophilia A
- Focus Adverse reactions
- Acronyms Explorer3
- Sponsors Novo Nordisk
- 01 Nov 2016 Status changed from active, no longer recruiting to completed.
- 20 Oct 2016 Status changed from recruiting to active, no longer recruiting.
- 19 Oct 2016 Planned End Date changed from 1 Mar 2017 to 1 Oct 2016.